公开(公告)号：EP2383295B1

公开(公告)日：2015-03-11

申请号：EP11166104.7

申请日：2004-12-10

申请人： E. R. Squibb & Sons, L.L.C.

发明人： Deshpande, Shrikant ,  Huang, Haichun ,  Srinivasan, Mohan ,  Cardarelli, Josephine M. ,  Wang, Changyu ,  Passmore, David ,  Rangan, Vangipuram S. ,  Lane, Thomas E. ,  Keirstead, Hans S. ,  Liu, Michael T.

IPC分类号： C07K16/24 ,  A61K39/395 ,  C12N5/18 ,  C07K14/52 ,  A61P37/06 ,  A61P31/04 ,  A61P31/12

CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K14/522 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP- 10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.